Paroxetine Hydrochloride (P129711 ≥98%, high purity) is an antidepressant widely prescribed for conditions such as major depressive disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and both generalized and social anxiety disorders. Classified as a selective serotonin reuptake inhibitor (SSRI), paroxetine works by blocking the presynaptic reuptake of serotonin, thereby increasing its extracellular concentration. This results in more serotonin being available to bind to postsynaptic receptors. Serotonin is a critical neurotransmitter involved in mood regulation, appetite control, and sleep, as well as certain cognitive processes including memory and learning.
Chemically, paroxetine is a phenylpiperidine derivative and is structurally distinct from older tricyclic and tetracyclic antidepressants. These earlier drug classes tend to be less selective and are associated with a higher incidence of unwanted side effects.
Although paroxetine has been in clinical use for over a decade, recent research continues to validate its therapeutic efficacy and uncover additional mechanisms of action. One area of interest involves its potential influence on epigenetic regulation—a key factor in psychiatric disease.
In particular, studies suggest that paroxetine indirectly modulates the activity of DNA methyltransferase 1 (DNMT1), the enzyme responsible for adding methyl groups to CpG dinucleotides in mammalian DNA. This modulation occurs through effects on histone methyltransferase (HMT) G9a, which activates DNMT1. Paroxetine treatment has been shown to lower G9a protein levels and disrupt the interaction between G9a and DNMT1. By influencing DNMT1 activity via G9a, paroxetine provides a potential link between small-molecule therapeutics, epigenetic pathways, and the treatment of psychiatric disorders.
References:
1. Anderson I. J Affect Disord. 2000 Apr;58(1):19-36.
2. Zimmermann N, Zschocke J, Perisic T, et al. Biochem J. 2012 Nov 15;448(1):93-102.
Aladdin: https://www.aladdinsci.com/